VaxHit also enables the identification of vaccines against selected intracellular pathogens. Vaxil is developing a Tuberculosis vaccine – MTBuVax™. This is a multi-antigenic, multi-epitopes subunit vaccine with epitopes derived from the SP domains of up to 5 known and novel MTb antigens. MTBuVax has already manifested superior immunity in a large number of blood samples derived from healthy individual and patient with active TB comparing to known peptide vaccines from the same antigens. It also performed robust cellular and humoral immunogenicity in mice. Vaxil strategy is to locate the best partner for clinical development of this vaccine.
VAXIL – Creating the ideal immunotherapy
Inducing a Broad
Cancer ResistanceLearn More
Immune ResponseLearn More
Cancer Stem CellsLearn More
First Ever SP-Specific
Antibody PlatformLearn More
Vaxil’s Lead Products and Orphan Drug Status
Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™platform is its ImMucin™ lead immunotherapy product.